Lynn Lee Lab

Publications

Itskovich, SS; Gurunathan, A; Clark, J; Burwinkel, M; Wunderlich, M; Berger, MR; Kulkarni, A; Chetal, K; Venkatasubramanian, M; Salomonis, N; Kumar, AR; Lee, LH. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nature Communications. 2020; 11:2369.

Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR. High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Blood Advances. 2020; 4:717-727.

Lee, LH; Gasilina, A; Roychoudhury, J; McCormack, FX; Pressey, J; Grimley, MS; Lorsbach, R; Ali, S; Bailey, M; Stephens, P; Ross, JS; Miller, VA; Nassar, NN; Kumar, AR. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI insight. 2017; 2:e89473.

Gracia-Maldonado, G; Clark, J; Burwinkel, M; Greenslade, B; Wunderlich, M; Salomonis, N; Leone, D; Gatti, E; Pierre, P; Kumar, AR; Lee, LH. LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. Haematologica: the hematology journal. 2022; 107:803-815.

Muto, T; Guillamot, M; Yeung, J; Fang, J; Bennett, J; Nadorp, B; Lasry, A; Redondo, LZ; Choi, K; Gong, Y; Lujambio, A; Lowe, SW; Aifantis, I; Starczynowski, DT. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022; 29:298-314.e9.

Lin, S; Larrue, C; Scheidegger, NK; Seong, BK A; Dharia, NV; Kuljanin, M; Wechsler, CS; Kugener, G; Robichaud, AL; Conway, AS; Wunderlich, M; Letai, A; Tamburini, J; Stegmaier, K. An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discovery. 2022; 12:432-449.

Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; Perentesis, JP; Pommert, L; Absalon, MJ. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Pediatric Blood and Cancer. 2021; 68:e29126.

Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL. Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology. 2020; 38:e22502.

Itskovich, SS; Gurunathan, A; Clark, J; Burwinkel, M; Wunderlich, M; Berger, MR; Kulkarni, A; Chetal, K; Venkatasubramanian, M; Salomonis, N; Kumar, AR; Lee, LH. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nature Communications. 2020; 11:2369.

Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR. High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Blood Advances. 2020; 4:717-727.

Lee, LH; Gasilina, A; Roychoudhury, J; McCormack, FX; Pressey, J; Grimley, MS; Lorsbach, R; Ali, S; Bailey, M; Stephens, P; Ross, JS; Miller, VA; Nassar, NN; Kumar, AR. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI insight. 2017; 2:e89473.